Relay Therapeutics (RLAY) Projected to Post Earnings on Thursday

Relay Therapeutics (NASDAQ:RLAY) is expected to be releasing its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.41) per share and revenue of $0.16 million for the quarter. Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:00 PM ET.

Relay Therapeutics (NASDAQ:RLAY) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.08. The company had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $0.07 million. On average, analysts expect Relay Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Relay Therapeutics Stock Performance

Shares of RLAY opened at $6.86 on Wednesday. The company’s 50 day moving average price is $5.38 and its 200 day moving average price is $4.05. Relay Therapeutics has a 52 week low of $1.77 and a 52 week high of $7.64. The company has a market capitalization of $1.18 billion, a PE ratio of -3.52 and a beta of 1.76.

Insider Buying and Selling

In other news, CFO Thomas Catinazzo sold 21,664 shares of the company’s stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $7.29, for a total transaction of $157,930.56. Following the completion of the sale, the chief financial officer owned 313,631 shares in the company, valued at approximately $2,286,369.99. This represents a 6.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Donald A. Bergstrom sold 30,897 shares of the company’s stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $7.29, for a total value of $225,239.13. Following the sale, the insider owned 521,823 shares of the company’s stock, valued at approximately $3,804,089.67. This trade represents a 5.59% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 155,163 shares of company stock worth $1,117,630. Insiders own 4.32% of the company’s stock.

Hedge Funds Weigh In On Relay Therapeutics

A number of institutional investors have recently modified their holdings of the company. AQR Capital Management LLC boosted its holdings in Relay Therapeutics by 11.9% during the first quarter. AQR Capital Management LLC now owns 364,946 shares of the company’s stock valued at $956,000 after acquiring an additional 38,812 shares during the period. Engineers Gate Manager LP boosted its holdings in Relay Therapeutics by 31.5% during the second quarter. Engineers Gate Manager LP now owns 38,719 shares of the company’s stock valued at $134,000 after acquiring an additional 9,281 shares during the period. BNP Paribas Financial Markets lifted its position in shares of Relay Therapeutics by 90.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 35,441 shares of the company’s stock worth $123,000 after purchasing an additional 16,851 shares during the last quarter. Sei Investments Co. acquired a new position in shares of Relay Therapeutics during the 2nd quarter worth about $89,000. Finally, Cresset Asset Management LLC lifted its position in shares of Relay Therapeutics by 26.2% during the 2nd quarter. Cresset Asset Management LLC now owns 37,084 shares of the company’s stock worth $128,000 after purchasing an additional 7,705 shares during the last quarter. Institutional investors own 96.98% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a report on Tuesday, October 14th. Guggenheim started coverage on Relay Therapeutics in a research report on Thursday, September 4th. They issued a “buy” rating and a $15.00 target price on the stock. HC Wainwright dropped their target price on Relay Therapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, August 26th. Finally, Raymond James Financial lowered their price target on Relay Therapeutics from $29.00 to $19.00 and set a “strong-buy” rating for the company in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.